Tradestie Institutional Equity Comparison Engine

EDIT vs CRSP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRSP Overall Edge

CRSP Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin, Momentum & Technical while EDIT counters with relative strength in Options & Structure. Fundamentally, EDIT trades at N/M Forward P/E with -167.0% operating margin (+37.4% YoY revenue) versus CRSP at 23.4x Forward P/E and -2058.6% operating margin (+1325.1% YoY). In options structure, EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro) against CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
EDIT N/M vs CRSP 23.4x Fwd P/E
Growth & Margin Winner CRSP
Op Margin -167.0% vs -2058.6% ยท YoY +37.4% vs +1325.1%
Momentum & Technical Winner CRSP
1Y -25.0% vs -20.5% ยท 52W Pos 11% vs 1%
Options & Structure Winner EDIT
BREAKDOWN (38th %ile IV) vs BREAKDOWN (52nd %ile IV)
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
1M Return -18.94%
1Y Return -25.0%
Forward P/E N/M
Unified AI Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EDIT -25.0% CRSP -20.54% Spread: +4.46 pp (CRSP Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period EDIT Revenue CRSP Revenue EDIT Op. Margin CRSP Op. Margin Margin Edge
FY2018 $30M $0M -356.1% -5087.8% EDIT
FY2019 $20M $290M -686.4% 16.1% CRSP
FY2020 $90M $0M -148.6% -49295.5% EDIT
FY2021 $30M $910M -756.1% 40.8% CRSP
FY2022 $20M $0M -1146.3% -56190.4% EDIT
FY2023 $80M $370M -216.6% -60.0% CRSP
FY2024 $30M $40M -777.2% -1250.4% EDIT
FY2025 $40M $0M -394.9% -18933.6% EDIT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EDIT (3) vs CRSP (7)
Institutional Metric EDIT CRSP Criterion Row Winner
Market Capitalization Scale $336.5M $4.1B Larger Scale CRSP
Trailing P/E Ratio Valuation N/M 23.4x Lower Multiple CRSP
Forward P/E Ratio Valuation N/M 23.4x Lower Multiple CRSP
Revenue Growth (YoY) Growth +37.4% +1325.1% Higher Growth CRSP
Operating Margin (TTM) Profitability -167.0% -2058.6% Higher Margin EDIT
Net Profit Margin Profitability -144.9% 0.0% Higher Margin CRSP
Return on Equity (ROE) Capital Efficiency -147.4% -25.6% Higher ROE CRSP
52-Week Range Position Momentum 11% ($2โ€“$4) 1% ($40โ€“$63) Stronger Trend EDIT
Beta / 30D Volatility Risk Regime 2.32ฮฒ ยท 102% Vol 1.85ฮฒ ยท 60% Vol Lower Realized Risk CRSP
Unified Institutional Score Composite Signal 48.4 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite EDIT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EDIT vs CRSP Buy Guide
EDIT BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 38th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EDIT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EDIT nor CRSP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.